Cumulative meta-analysis of interleukins 6 and 1β, tumour necrosis factor α and C-reactive protein in patients with major depressive disorder.
Haapakoski R, Mathieu J, Ebmeier KP, Alenius H, Kivimäki M. · 2015
Read Cumulative meta-analysis of interleukins 6 and 1β, tumour necrosis factor α and C-reactive protein in patients with major depressive disorder. by Haapakoski R, Mathieu J, Ebmeier KP, Alenius H, Kivimäki M. (2015) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc4566946.txt.
Introduction
Rita Haapakoski and four co-authors run a running tally of inflammation in depression, in Brain, Behavior, and Immunity in 2015. Major depression is a leading cause of disability, and one theory blames a constantly aroused innate immune system. Blood studies had found higher inflammatory signals in depressed people, but the strength of proof varied by marker.
A cumulative meta-analysis adds each new study in date order, showing when the evidence settled. The method confirmed a robust link between depression and two markers: interleukin-6 and C-reactive protein. For tumor necrosis factor and interleukin-1β, the signal stayed uncertain. The authors call for deeper work on how interleukin-6 and C-reactive protein act, and whether calming them can treat depression.
Catalog record
| CREATOR | Haapakoski R, Mathieu J, Ebmeier KP, Alenius H, Kivimäki M. |
|---|---|
| YEAR | 2015 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 59 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Cumulative meta-analysis of interleukins 6 and 1β, tumour necrosis factor α and C-reactive protein in patients with major depressive disorder By Rita Haapakoski, Julia Mathieu, Klaus P Ebmeier, Harri Alenius, Mika Kivimäki Published in: Brain, Behavior, and Immunity DOI: 10.1016/j.bbi.2015.06.001 ABSTRACT Highlights - •This meta-analysis confirms a robust link between IL-6, CRP and major depression. - •The role of TNF-α and IL-1β in major depression remains uncertain. - •Further mechanistic and immunotherapeutic studies on IL-6 and CRP are needed. Keywords: Major depression, Inflammation, Interleukin-6, Interleukin-1β, Tumour necrosis factor-α, C-reactive protein, Cumulative meta-analysis INTRODUCTION Major depressive disorder (MDD) is a leading cause of disability and an important contributing factor to the worldwide burden of disease; it can directly cause mortality due to suicide and indirectly through affecting prognosis of chronic conditions such as ischemic heart disease (Whiteford et al., 2013). The inflammation hypothesis of depression proposes that MDD is also associated with sustained activation of the innate immune system leading to increased production of proinflammatory cytokines and acute phase proteins (Maes, 1995; Smith, 1991). In support of this hypothesis, several studies have detected higher levels of inflammation in depressed individuals than in healthy controls, although the strength of evidence varies depending on which specific inflammatory markers have been examined, i.e. interleukin (IL)-6, IL-1β, tumour necrosis factor (TNF)-α and C-reactive protein (CRP) (Dowlati et al., 2010; Hiles et al., 2012b; Howren et al., 2009; Liu et al., 2012; Valkanova et al., 2013). In a cumulative meta-analysis, the results from individual studies are added chronologically and the aggregate effect estimate recomputed after addition of each study. The purpose of this technique is to determine the point at which further studies carried out in a similar manner are unlikely to change the conclusion. Importantly, information in these analyses may help researchers to justify additional studies or to become aware of the need for redirecting their research efforts (Clarke et al., 2014). Here, we have applied this approach to evaluate the strength of the association between specific inflammatory markers (IL-6, IL-1β, CRP-α, TNF) and MDD. MATERIALS AND METHODS Literature search and data extraction 2.1. We performed a systematic search of the literature using PubMed, Embase, PsychInfo to include publications until May 2014 with the following search terms: [“depression”], [“depressive”], [“C-reactive protein”], [“CRP”], [“interleukin 6”], [“IL-6”], [“tumour necrosis factor α”], [TNF-alpha”], [“interleukin 1β”], [IL-1beta”], [“cytokine”]. We also scrutinised the reference lists of all of the relevant publications identified. In addition, we used the Institute of Scientific Information Web of Science (May 2014) to retrieve all the studies citing the studies identified by the search. Information from the articles included in the meta-analysis reporting an association between CRP (Howren et al., 2009), IL-6, TNF-α, IL-1β (Dowlati et al., 2010; Hiles et al., 2012b; Howren et al., 2009; Liu et al., 2012) and depression in cross-sectional settings was reviewed and retracted. Data were searched and extracted independently by two authors (RH and JM), the results were compared and consensus obtained through discussion. Supplementary Fig. 1 shows the literature search strategy. Selection criteria 2.2. The immune markers evaluated in this study were selected based on their effects on the development of sickness behaviour (IL-1β and TNF-α) (Dantzer, 2001; Dantzer et al., 2008) and previous meta-analyses suggesting possible associations of peripheral levels of IL-1, (Howren et al., 2009) TNF-α, (Dowlati et al., 2010; Liu et al., 2012) and IL-6, (Dowlati et al., 2010; Hiles et al., 2012b; Liu et al., 2012) CRP (Howren et al., 2009) with depression. Previous meta-analyses did not support the involvement of IL-10, (Dowlati et al., 2010; Hiles et al., 2012b; Liu et al., 2012) IL-4, (Dowlati et al., 2010; Liu et al., 2012) IL-8, (Dowlati et al., 2010; Liu et al., 2012) IL-2, (Dowlati et al., 2010; Liu et al., 2012) or IFN-γ (Dowlati et al., 2010; Liu et al., 2012) in depression, and therefore these cytokines were not included in this analysis. Specific inclusion criteria were (1) measurement of unstimulated cytokines from the blood; (2) comparison of adult patients with MDD and psychiatrically healthy controls; (3) use of structured clinical assessments (SCID or MINI) based on DSM-III/DSM-IV criteria to verify unipolar MDD; (4) incorporation of study subjects without major physical illness (i.e. diabetes, heart disease, cancer etc.) at the time of assessment. Studies focusing on pregnant women, postpartum depression or including patients with metabolic syndrome were excluded from the meta-analysis, whereas studies targeting patients with stable medical conditions, such as hypertension were included. Studies where participants used any medications at the time of blood sampling were referred to as “subjects using medication”. Individuals that had undergone a washout period from antidepressants before entering the study or at the time of immune assessments were referred to as “subjects not using antidepressant medication”. The median washout period in the included studies was 4 weeks with a range between 1 week and 3 months (Supplementary Table 3). Quality assessment 2.3. This meta-analysis was conducted according to PRISMA guidelines (Moher et al., 2009). For evaluation of the quality of included studies, we used the Newcastle-Ottawa quality assessment scale (NOS) for case-control studies (Wells et al., 2009) In this method, each study can obtain a maximum of 9 points in three categories; selection of study participants (adequate definition, validation and representativeness of cases and controls), comparability of cases and controls, and the ascertainment of exposure (Supplementary Table 1). In line with the recommendations of the Meta-Analysis of Observational Studies, (Stroup et al., 2000), we performed a sensitivity analysis excluding those studies with poor quality (NOS score < 6). We also performed an additional quality analysis using the score of 7 as the cut-off value. Data synthesis 2.4. The statistical package Comprehensive Meta-analysis (version 2) was used for data analysis. Effect sizes were calculated using standardised mean differences (Cohen’s d) from mean (±SD) concentrations of each immune marker measured in the blood of MDD patients and non-depressed controls. If concentrations of immune markers were not reported, we extracted the effect size from exact p-values and sample size (Dahl et al., 2014; Euteneuer et al., 2011; Hornig et al., 1998; Li et al., 2013). When relevant data were not reported, (Grassi-Oliveira et al., 2009; Maes et al., 1995b; Weinstein et al., 2010; Yang et al., 2007) we first contacted the authors for assistance and if not successful, retrieved values from graphs using DataThief III, version 1.6. (Tummers et al., 2008). A cumulative meta-analysis was performed by sorting of the included studies according to the date of publication. The p-values represent the summary statistics of all incorporated studies (rather than p-values for independent studies), enabling the inspection of the contribution of each new study to the overall effect estimate. Due to the variation in effect sizes across studies and to achieve generalisation of the results, a random-effects model was used in the analysis of total data and in the meta-regression. Random-effects models take into account both within- and between-study variability, and provide a more conservative estimate of effect sizes than can be obtained with the fixed-effect models. Heterogeneity across studies was assessed using Cochrane’s Q and p < 0.10 was considered as significant. The I2 index < 25% was defined as ‘low’, 50% as ‘moderate’ and 75% ‘high’ heterogeneity (Higgins et al.,